Skip to main content
NCBI home page
American Journal of Human Genetics logoLink to American Journal of Human Genetics
. 1997 Aug;61(2):310–316. doi: 10.1086/514846

Spectrum of mutations in the Batten disease gene, CLN3.

P B Munroe 1, H M Mitchison 1, A M O'Rawe 1, J W Anderson 1, R M Boustany 1, T J Lerner 1, P E Taschner 1, N de Vos 1, M H Breuning 1, R M Gardiner 1, S E Mole 1
PMCID: PMC1715900  PMID: 9311735

Abstract

Batten disease (juvenile-onset neuronal ceroid lipofuscinosis [JNCL]) is an autosomal recessive condition characterized by accumulation of lipopigments (lipofuscin and ceroid) in neurons and other cell types. The Batten disease gene, CLN3, was recently isolated, and four disease-causing mutations were identified, including a 1.02-kb deletion that is present in the majority of patients (The International Batten Disease Consortium 1995). One hundred eighty-eight unrelated patients with JNCL were screened in this study to determine how many disease chromosomes carried the 1.02-kb deletion and how many carried other mutations in CLN3. One hundred thirty-nine patients (74%) were found to have the 1.02-kb deletion on both chromosomes, whereas 49 patients (41 heterozygous for the 1.02-kb deletion) had mutations other than the 1.02-kb deletion. SSCP analysis and direct sequencing were used to screen for new mutations in these individuals. Nineteen novel mutations were found: six missense mutations, five nonsense mutations, three small deletions, three small insertions, one intronic mutation, and one splice-site mutation. This report brings the total number of disease-associated mutations in CLN3 to 23. All patients homozygous for mutations predicted to give rise to truncated proteins were found to have classical JNCL. However, a proportion of the patients (n = 4) who were compound heterozygotes for a missense mutation and the 1.02-kb deletion were found to display an atypical phenotype that was dominated by visual failure rather than by severe neurodegeneration. All missense mutations were found to affect residues conserved between the human protein and homologues in diverse species.

Full text

PDF
310

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amaral O., Fortuna A. M., Lacerda L., Pinto R., Sa Miranda M. C. Molecular characterisation of type 1 Gaucher disease families and patients: intrafamilial heterogeneity at the clinical level. J Med Genet. 1994 May;31(5):401–404. doi: 10.1136/jmg.31.5.401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Callen D. F., Baker E., Lane S., Nancarrow J., Thompson A., Whitmore S. A., MacLennan D. H., Berger R., Cherif D., Järvelä I. Regional mapping of the Batten disease locus (CLN3) to human chromosome 16p12. Am J Hum Genet. 1991 Dec;49(6):1372–1377. [PMC free article] [PubMed] [Google Scholar]
  3. Dean M., White M. B., Amos J., Gerrard B., Stewart C., Khaw K. T., Leppert M. Multiple mutations in highly conserved residues are found in mildly affected cystic fibrosis patients. Cell. 1990 Jun 1;61(5):863–870. doi: 10.1016/0092-8674(90)90196-l. [DOI] [PubMed] [Google Scholar]
  4. Gardiner M., Sandford A., Deadman M., Poulton J., Cookson W., Reeders S., Jokiaho I., Peltonen L., Eiberg H., Julier C. Batten disease (Spielmeyer-Vogt disease, juvenile onset neuronal ceroid-lipofuscinosis) gene (CLN3) maps to human chromosome 16. Genomics. 1990 Oct;8(2):387–390. doi: 10.1016/0888-7543(90)90297-8. [DOI] [PubMed] [Google Scholar]
  5. Janes R. W., Munroe P. B., Mitchison H. M., Gardiner R. M., Mole S. E., Wallace B. A. A model for Batten disease protein CLN3: functional implications from homology and mutations. FEBS Lett. 1996 Dec 9;399(1-2):75–77. doi: 10.1016/s0014-5793(96)01290-2. [DOI] [PubMed] [Google Scholar]
  6. Lee R. L., Johnson K. R., Lerner T. J. Isolation and chromosomal mapping of a mouse homolog of the Batten disease gene CLN3. Genomics. 1996 Aug 1;35(3):617–619. doi: 10.1006/geno.1996.0410. [DOI] [PubMed] [Google Scholar]
  7. Lerner T. J., Boustany R. M., MacCormack K., Gleitsman J., Schlumpf K., Breakefield X. O., Gusella J. F., Haines J. L. Linkage disequilibrium between the juvenile neuronal ceroid lipofuscinosis gene and marker loci on chromosome 16p 12.1. Am J Hum Genet. 1994 Jan;54(1):88–94. [PMC free article] [PubMed] [Google Scholar]
  8. Mitchison H. M., Munroe P. B., O'Rawe A. M., Taschner P. E., de Vos N., Kremmidiotis G., Lensink I., Munk A. C., D'Arigo K. L., Anderson J. W. Genomic structure and complete nucleotide sequence of the Batten disease gene, CLN3. Genomics. 1997 Mar 1;40(2):346–350. doi: 10.1006/geno.1996.4576. [DOI] [PubMed] [Google Scholar]
  9. Mitchison H. M., O'Rawe A. M., Taschner P. E., Sandkuijl L. A., Santavuori P., de Vos N., Breuning M. H., Mole S. E., Gardiner R. M., Järvelä I. E. Batten disease gene, CLN3: linkage disequilibrium mapping in the Finnish population, and analysis of European haplotypes. Am J Hum Genet. 1995 Mar;56(3):654–662. [PMC free article] [PubMed] [Google Scholar]
  10. Mitchison H. M., Taschner P. E., O'Rawe A. M., de Vos N., Phillips H. A., Thompson A. D., Kozman H. M., Haines J. L., Schlumpf K., D'Arigo K. Genetic mapping of the Batten disease locus (CLN3) to the interval D16S288-D16S383 by analysis of haplotypes and allelic association. Genomics. 1994 Jul 15;22(2):465–468. doi: 10.1006/geno.1994.1412. [DOI] [PubMed] [Google Scholar]
  11. Mitchison H. M., Thompson A. D., Mulley J. C., Kozman H. M., Richards R. I., Callen D. F., Stallings R. L., Doggett N. A., Attwood J., McKay T. R. Fine genetic mapping of the Batten disease locus (CLN3) by haplotype analysis and demonstration of allelic association with chromosome 16p microsatellite loci. Genomics. 1993 May;16(2):455–460. doi: 10.1006/geno.1993.1210. [DOI] [PubMed] [Google Scholar]
  12. Munroe P. B., Rapola J., Mitchison H. M., Mustonen A., Mole S. E., Gardiner R. M., Jarvela I. Prenatal diagnosis of Batten's disease. Lancet. 1996 Apr 13;347(9007):1014–1015. doi: 10.1016/s0140-6736(96)90148-8. [DOI] [PubMed] [Google Scholar]
  13. Sanger F., Nicklen S., Coulson A. R. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977 Dec;74(12):5463–5467. doi: 10.1073/pnas.74.12.5463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Santavuori P. Neuronal ceroid-lipofuscinoses in childhood. Brain Dev. 1988;10(2):80–83. doi: 10.1016/s0387-7604(88)80075-5. [DOI] [PubMed] [Google Scholar]
  15. Tyfield L. A., Zschocke J., Stephenson A., Cockburn F., Harvie A., Bidwell J. L., Wood N. A., Hunt L. P. Discordant phenylketonuria phenotypes in one family: the relationship between genotype and clinical outcome is a function of multiple effects. J Med Genet. 1995 Nov;32(11):867–870. doi: 10.1136/jmg.32.11.867. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Wisniewski K. E., Rapin I., Heaney-Kieras J. Clinico-pathological variability in the childhood neuronal ceroid-lipofuscinoses and new observations on glycoprotein abnormalities. Am J Med Genet Suppl. 1988;5:27–46. doi: 10.1002/ajmg.1320310607. [DOI] [PubMed] [Google Scholar]
  17. Yan W., Boustany R. M., Konradi C., Ozelius L., Lerner T., Trofatter J. A., Julier C., Breakefield X. O., Gusella J. F., Haines J. L. Localization of juvenile, but not late-infantile, neuronal ceroid lipofuscinosis on chromosome 16. Am J Hum Genet. 1993 Jan;52(1):89–95. [PMC free article] [PubMed] [Google Scholar]
  18. Zeman W. Presidential address: Studies in the neuronal ceroid-lipofuscinoses. J Neuropathol Exp Neurol. 1974 Jan;33(1):1–12. doi: 10.1097/00005072-197401000-00001. [DOI] [PubMed] [Google Scholar]

Articles from American Journal of Human Genetics are provided here courtesy of American Society of Human Genetics

RESOURCES